Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -74.50% is 53% above its 5-year average of -158.82%, near the high end of its 5-year range (-258.47%–-74.50%).
66.20% above its 12-month average of -220.41%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 2.01%.
RETURN ON ASSETS (ROA)
-74.50%
RETURN ON ASSETS (ROA) AVG TTM
-220.41%
RETURN ON ASSETS (ROA) AVG 3Y
-182.97%
RETURN ON ASSETS (ROA) AVG 5Y
-158.82%
RETURN ON ASSETS (ROA) AVG 10Y
-217.78%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+66.20%
CURRENT VS 3Y AVG
+59.28%
CURRENT VS 5Y AVG
+53.09%
CURRENT VS 10Y AVG
+65.79%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.80%
median of 816 covered companies
CURRENT VS SECTOR MEDIAN
-134.28%
vs the sector median at left
ENDRA Life Sciences Inc.
Market Cap
$7.81M
Return on Assets (ROA)
-74.50%
TTM Avg
-220.41%
3Y Avg
-182.97%
5Y Avg
-158.82%
Market Cap
$7.93M
Return on Assets (ROA)
86.37%
TTM Avg
-66.33%
3Y Avg
-66.09%
5Y Avg
-69.89%
Market Cap
$8.01M
Return on Assets (ROA)
-76.12%
TTM Avg
-177.28%
3Y Avg
-394.98%
5Y Avg
-300.85%
Market Cap
$7.95M
Return on Assets (ROA)
-381.53%
TTM Avg
-330.40%
3Y Avg
-209.86%
5Y Avg
-253.27%
Market Cap
$7.59M
Return on Assets (ROA)
-74.58%
TTM Avg
-69.72%
3Y Avg
-51.64%
5Y Avg
-52.44%
Market Cap
$8.13M
Return on Assets (ROA)
-29.10%
TTM Avg
-66.56%
3Y Avg
-142.45%
5Y Avg
-115.37%
Market Cap
$8.18M
Return on Assets (ROA)
N/A
TTM Avg
-103.86%
3Y Avg
-117.64%
5Y Avg
-138.14%
Market Cap
$7.31M
Return on Assets (ROA)
-457.62%
TTM Avg
-117.02%
3Y Avg
-190.78%
5Y Avg
-182.53%
Market Cap
$7.31M
Return on Assets (ROA)
-414.54%
TTM Avg
-226.50%
3Y Avg
-135.75%
5Y Avg
-126.75%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ENDRA Life Sciences Inc. (NDRA) | $7.81M | -74.50% | -220.41% | -182.97% | -158.82% |
| Traws Pharma, Inc. (TRAW)vs › | $7.93M | 86.37% | -66.33% | -66.09% | -69.89% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $8.01M | -76.12% | -177.28% | -394.98% | -300.85% |
| GT Biopharma, Inc. (GTBP)vs › | $7.95M | -381.53% | -330.40% | -209.86% | -253.27% |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.59M | -74.58% | -69.72% | -51.64% | -52.44% |
| Aprea Therapeutics, Inc. (APRE)vs › | $8.13M | -29.10% | -66.56% | -142.45% | -115.37% |
| HeartSciences Inc. (HSCS)vs › | $8.18M | N/A | -103.86% | -117.64% | -138.14% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.31M | -457.62% | -117.02% | -190.78% | -182.53% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -414.54% | -226.50% | -135.75% | -126.75% |
| Longeveron Inc. (LGVN)vs › | $7.27M | -151.57% | -141.88% | -132.44% | -101.65% |
ROA
-74.5%
ROE
-93.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -182.35% |
| 2024-12-31 | -258.47% |
| 2023-12-31 | -148.95% |
| 2022-12-31 | -142.11% |
| 2021-12-31 | -87.24% |
| 2020-12-31 | -133.78% |
| 2019-12-31 | -185.42% |
| 2018-12-31 | -135.63% |
| 2017-12-31 | -87.81% |
| 2016-12-31 | -565.52% |
| 2015-12-31 | -468.28% |
| 2014-12-31 | -310.25% |
